オピオイド誘発性便秘(OIC):治療薬開発パイプライン動向(2014年下半期)

◆英語タイトル:Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2014
◆商品コード:GMDHC5266IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年7月31日
◆ページ数:94
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2014’, provides an overview of the Opioid-Induced Constipation (OIC)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Opioid-Induced Constipation (OIC) Overview 8
Therapeutics Development 9
Pipeline Products for Opioid-Induced Constipation (OIC) – Overview 9
Pipeline Products for Opioid-Induced Constipation (OIC) – Comparative Analysis 10
Opioid-Induced Constipation (OIC) – Therapeutics under Development by Companies 11
Opioid-Induced Constipation (OIC) – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Opioid-Induced Constipation (OIC) – Products under Development by Companies 16
Opioid-Induced Constipation (OIC) – Companies Involved in Therapeutics Development 17
Shionogi & Co., Ltd. 17
AstraZeneca PLC 18
Cubist Pharmaceuticals, Inc. 19
Progenics Pharmaceuticals, Inc. 20
Cosmo Pharmaceuticals S.p.A 21
Sucampo Pharmaceuticals, Inc. 22
Ironwood Pharmaceuticals, Inc. 23
AIKO Biotechnology, Inc. 24
Synergy Pharmaceuticals, Inc. 25
S.L.A. Pharma AG 26
Develco Pharma Schweiz AG 27
Opioid-Induced Constipation (OIC) – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
naloxegol – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lubiprostone – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
methylnaltrexone bromide – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
naldemedine – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
bevenopran – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
naloxone hydrochloride PR – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
methylnaltrexone bromide – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
axelopran – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
naloxone hydrochloride SR – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SP-333 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
linaclotide – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
naloxone hydrochloride – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(6-beta-naltrexol + oxycodone) – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Opioid-Induced Constipation (OIC) – Recent Pipeline Updates 63
Opioid-Induced Constipation (OIC) – Dormant Projects 82
Opioid-Induced Constipation (OIC) – Discontinued Products 83
Opioid-Induced Constipation (OIC) – Product Development Milestones 84
Featured News & Press Releases 84
Jul 23, 2014: Sucampo Announces Publication of NICE Recommendation for AMITIZA (Lubiprostone) 84
Jul 17, 2014: Synergy Pharmaceuticals Completes Patient Enrollment for its SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation 84
Jul 14, 2014: FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain 85
Jul 07, 2014: Swissmedic Approves AMITIZA (Lubiprostone) for the Treatment of Opioid-Induced Constipation 86
Jun 19, 2014: Data Published In The New England Journal Of Medicine Demonstrate Naloxegol Improved Opioid-Induced Constipation In Chronic Pain Patients 86
Jun 17, 2014: AMITIZA (Lubiprostone) Receives NICE Recommendation 88
Jun 12, 2014: Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting’s Vote 89
Jun 12, 2014: FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC 89
Jun 12, 2014: US FDA advisory committee recommends no cardiovascular outcomes trial for peripherally-Acting MU-Opioid Receptor Antagonist (Pamora) class including Movantik 90
Jun 04, 2014: Drug trial shows promise for treating constipation caused by pain medicines 91
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94

List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2014 9
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H2 2014 17
Opioid-Induced Constipation (OIC) - Pipeline by AstraZeneca PLC, H2 2014 18
Opioid-Induced Constipation (OIC) - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 19
Opioid-Induced Constipation (OIC) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 20
Opioid-Induced Constipation (OIC) - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 21
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 22
Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 23
Opioid-Induced Constipation (OIC) - Pipeline by AIKO Biotechnology, Inc., H2 2014 24
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H2 2014 25
Opioid-Induced Constipation (OIC) - Pipeline by S.L.A. Pharma AG, H2 2014 26
Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Assessment by Combination Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H2 2014 63
Opioid-Induced Constipation (OIC) - Dormant Projects, H2 2014 82
Opioid-Induced Constipation (OIC) - Discontinued Products, H2 2014 83

List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2014 9
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Top 10 Target, H2 2014 30
Number of Products by Stage and Top 10 Target, H2 2014 31
Number of Products by Top 10 Mechanism of Action, H2 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 34
Number of Products by Top 10 Route of Administration, H2 2014 36
Number of Products by Stage and Top 10 Route of Administration, H2 2014 37
Number of Products by Top 10 Molecule Type, H2 2014 38
Number of Products by Stage and Top 10 Molecule Type, H2 2014 39

【掲載企業】

Shionogi & Co., Ltd.
AstraZeneca PLC
Cubist Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Cosmo Pharmaceuticals S.p.A
Sucampo Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
AIKO Biotechnology, Inc.
Synergy Pharmaceuticals, Inc.
S.L.A. Pharma AG
Develco Pharma Schweiz AG

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[オピオイド誘発性便秘(OIC):治療薬開発パイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆